Chen-Yuan Chiang
Overview
Explore the profile of Chen-Yuan Chiang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
1708
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goodall R, Nunn A, Meredith S, Bayissa A, Bhatnagar A, Chiang C, et al.
Lancet Respir Med
. 2024 Oct;
12(12):975-987.
PMID: 39366400
Background: STREAM stage 2 showed that two bedaquiline-containing regimens (a 9-month all-oral regimen and a 6-month regimen with 8 weeks of aminoglycoside) had superior efficacy to a 9-month injectable-containing regimen...
2.
Fabiane S, Chiang C, Meredith S, Gurumurthy M, Bayissa A, Nunn A, et al.
Trop Med Infect Dis
. 2024 Sep;
9(9).
PMID: 39330900
(1) Background: The World Health Organisation (WHO) categorises moxifloxacin and levofloxacin as Group A drugs, which should be prioritised in the treatment of rifampicin-resistant tuberculosis. We compare their relative efficacy...
3.
Lin C, Chen J, Chien S, Huang Y, Lin C, Lee J, et al.
J Microbiol Immunol Infect
. 2024 Aug;
57(5):791-800.
PMID: 39160114
Background: Bedaquiline, delamanid and fluoroquinolones are associated with increased QTcF. Whether clofazimine is associated with QTcF prolongation is less clear. Methods: All patients with rifampicin-resistant TB enrolled between May 2017...
4.
Shaw E, Stoker N, Potter J, Claassen H, Leslie A, Tweed C, et al.
Lancet Microbe
. 2024 Jul;
5(12):100909.
PMID: 39074472
Tuberculosis drug development has stagnated for decades, so the recent availability of bedaquiline is welcome. Bedaquiline-containing regimens, now the first-line therapy recommended by WHO, have transformed the treatment of drug-resistant...
5.
Cirillo D, Anthony R, Gagneux S, Horsburgh Jr C, Hasan R, Darboe S, et al.
Lancet Glob Health
. 2024 Jul;
12(8):e1225-e1226.
PMID: 39030054
No abstract available.
6.
Huang Y, Yu M, Lin C, Lee J, Lin C, Chien S, et al.
J Microbiol Immunol Infect
. 2024 May;
57(4):617-628.
PMID: 38705821
Background: Pre-extensively drug-resistant tuberculosis (pre-XDR-TB), defined as multidrug-resistant TB (MDR-TB) with additional resistance to any fluoroquinolone (FQ) is difficult to treat. We assessed whether the use of new or repurposed...
7.
Chiang C, Bern H, Goodall R, Chien S, Rusen I, Nunn A
BMC Infect Dis
. 2024 Jan;
24(1):144.
PMID: 38291393
Background: Stage 1 of the STREAM trial demonstrated that the 9 month (Short) regimen developed in Bangladesh was non-inferior to the 20 month (Long) 2011 World Health Organization recommended regimen....
8.
Chiang C, Lin C, Chien S, Wang C, Huang Y, Huang W, et al.
J Microbiol Immunol Infect
. 2023 Oct;
56(6):1245-1252.
PMID: 37802687
Background: Presumptive tuberculosis (TB) cases commonly had two to three sputum examinations in Taiwan. The incremental yield of serial sputum examinations has not been assessed before. Methods: In a pragmatic...
9.
Chiang C, Chen C, Feng J, Chiang Y, Huang W, Lin Y, et al.
J Formos Med Assoc
. 2023 May;
122(10):976-985.
PMID: 37183074
Solid organ transplant recipients have an increased risk of tuberculosis (TB). Due to the use of immunosuppressants, the incidence of TB among solid organ transplant recipients has been consistently reported...
10.
Garcia-Marcos L, Chiang C, Asher M, Marks G, El Sony A, Masekela R, et al.
Lancet Glob Health
. 2023 Jan;
11(2):e218-e228.
PMID: 36669806
Background: Asthma is one of the most common non-communicable diseases globally. This study aimed to assess asthma medicine use, management plan availability, and disease control in childhood, adolescence, and adulthood...